Clinical efficacy of endoscopic injections of OK-432 in the treatment of gastric cancer

Scand J Gastroenterol. 1988 Jun;23(5):539-45. doi: 10.3109/00365528809093908.


A total of 48 patients with gastric cancer were randomly assigned to receive either endoscopic injections of OK-432 plus systemic treatment with intravenously administered 5-fluorouracil and intradermally injected OK-432 (group A) or systemic therapy alone (group B). Morphologic improvement occurred in 7 of the 22 patients in group A. In one patient the tumor mass disappeared completely. In group B morphologic improvement occurred in only 2 of the 26 patients. The survival rate throughout the 24-month period was significantly (P less than 0.01) higher in group A than in group B patients. Thus, local administration of OK-432 by endoscopic injection is effective and is recommended for the treatment of patients with advanced gastric cancer.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Administration, Topical
  • Aged
  • Biological Products / administration & dosage*
  • Clinical Trials as Topic
  • Female
  • Fluorouracil / administration & dosage
  • Gastroscopy
  • Humans
  • Injections, Intradermal
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Picibanil / administration & dosage*
  • Prognosis
  • Random Allocation
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / pathology


  • Biological Products
  • Picibanil
  • Fluorouracil